| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NM0196-72 |
| P698 | PubMed publication ID | 8564846 |
| P50 | author | Denise Galloway | Q91250425 |
| P2093 | author name string | F Y Lee | |
| A F Wahl | |||
| K L Donaldson | |||
| S A Foster | |||
| C Fairchild | |||
| G W Demers | |||
| P2860 | cites work | WAF1, a potential mediator of p53 tumor suppression | Q27861121 |
| Identification of p53 as a sequence-specific DNA-binding protein | Q28282745 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 | Q29547773 | ||
| p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 | ||
| p53 is required for radiation-induced apoptosis in mouse thymocytes | Q29620281 | ||
| Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study | Q33489695 | ||
| Human placental cells transformed by tsA mutants of simian virus 40: a model system for the study of placental functions | Q33968570 | ||
| Monoclonal antibodies specific for simian virus 40 tumor antigens | Q34249232 | ||
| Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. | Q35230883 | ||
| Mechanism of action of taxol | Q35255662 | ||
| Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells | Q35476763 | ||
| Taxol stabilizes microtubules in mouse fibroblast cells | Q36360499 | ||
| p53 mutations increase resistance to ionizing radiation | Q36373753 | ||
| Induction of cellular p53 activity by DNA-damaging agents and growth arrest. | Q36690595 | ||
| Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma | Q40687772 | ||
| Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines | Q41520126 | ||
| Association of human papillomavirus types 16 and 18 E6 proteins with p53. | Q43701619 | ||
| MAP kinase becomes stably activated at metaphase and is associated with microtubule-organizing centers during meiotic maturation of mouse oocytes. | Q49137334 | ||
| Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. | Q52512094 | ||
| Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. | Q53505779 | ||
| Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. | Q54201959 | ||
| Thymocyte apoptosis induced by p53-dependent and independent pathways. | Q54242475 | ||
| A p53-dependent mouse spindle checkpoint | Q56445949 | ||
| A deadly inheritance | Q59053969 | ||
| Shared actions of endotoxin and taxol on TNF receptors and TNF release | Q68086156 | ||
| Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans | Q72354126 | ||
| Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor | Q72521166 | ||
| European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion | Q72880127 | ||
| P433 | issue | 1 | |
| P921 | main subject | paclitaxel | Q423762 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 72-79 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis | |
| P478 | volume | 2 |
| Q92481531 | 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers |
| Q44141797 | A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck |
| Q44759597 | A Pilot Study of Chemoradiotherapy With Weekly Docetaxel for Thoracic Esophageal Carcinoma With T4 and/or M1 Lymph Node Metastasis |
| Q37589239 | A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors |
| Q33516915 | A new isoquinolinium derivative, Cadein1, preferentially induces apoptosis in p53-defective cancer cells with functional mismatch repair via a p38-dependent pathway |
| Q40640289 | A novel c-kit positive biphenotypic acute leukemia cell line, TMBL-1, carrying a p53 point mutation |
| Q34552027 | A novel pentamethoxyflavone down-regulates tumor cell survival and proliferative and angiogenic gene products through inhibition of IκB kinase activation and sensitizes tumor cells to apoptosis by cytokines and chemotherapeutic agents. |
| Q36294890 | A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer |
| Q36696776 | A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer |
| Q36737086 | A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. |
| Q40807758 | A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes |
| Q41126929 | Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells |
| Q36177359 | Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents |
| Q80830503 | Alternol inhibits proliferation and induces apoptosis in mouse lymphocyte leukemia (L1210) cells |
| Q33800817 | An image-based, high-throughput screening assay for molecules that induce excess DNA replication in human cancer cells |
| Q77227817 | An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies |
| Q33654566 | An update on radiation therapy in breast cancer |
| Q36623220 | Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status |
| Q41076902 | Anti-apoptotic activity of low levels of wild-type p53. |
| Q55091443 | Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. |
| Q36085436 | Antitumor evaluation of two selected Pakistani plant extracts on human bone and breast cancer cell lines |
| Q73468224 | Apoptosis and cutaneous biology |
| Q41737530 | Apoptosis by p53: mechanisms, regulation, and clinical implications |
| Q40458245 | Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. |
| Q36323387 | Arrest of mammalian fibroblasts in G1 in response to actin inhibition is dependent on retinoblastoma pocket proteins but not on p53 |
| Q41824137 | Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers |
| Q74245221 | Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma |
| Q57463137 | BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression |
| Q81608794 | Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas |
| Q40665228 | Biological basis for chemo-radiotherapy interactions |
| Q35567256 | Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs |
| Q33916340 | Carcinogenic effects of ptaquiloside in bracken fern and related compounds |
| Q40782148 | Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells |
| Q44691785 | Cell status--dead or alive? |
| Q42829823 | Centrosome and spindle pole microtubules are main targets of a fluorescent taxoid inducing cell death. |
| Q35974979 | Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity |
| Q73574213 | Chemotherapy for recurrent ovarian cancer |
| Q40901484 | Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways |
| Q28363906 | Cisplatinum and taxol induce different patterns of p53 phosphorylation |
| Q35127312 | Clinical Implication of p53 Mutation in Lung Cancer |
| Q24806527 | Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group |
| Q73594102 | Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene |
| Q34785152 | Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection |
| Q48283141 | Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation |
| Q40574551 | Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure |
| Q33249461 | Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. |
| Q73905123 | Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines |
| Q37089273 | DNA damage and p53-mediated cell cycle arrest: a reevaluation. |
| Q38309088 | Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress. |
| Q36294984 | Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma |
| Q24682740 | Dido disruption leads to centrosome amplification and mitotic checkpoint defects compromising chromosome stability |
| Q41155486 | Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells |
| Q79366828 | Distinct subtypes of serous ovarian carcinoma identified by p53 determination |
| Q48541625 | Disulfide-masked iron prochelators: Effects on cell death, proliferation, and hemoglobin production |
| Q41541911 | Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). |
| Q90450359 | Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study |
| Q36809577 | Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. |
| Q34785151 | Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis. |
| Q30438642 | Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. |
| Q39777499 | Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. |
| Q51836563 | Effect of microcystin-LR and cyanobacterial extract from Polish reservoir of drinking water on cell cycle progression, mitotic spindle, and apoptosis in CHO-K1 cells. |
| Q42548550 | Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction |
| Q40679747 | Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells |
| Q35971203 | Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines. |
| Q36530680 | Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer |
| Q36612301 | Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies |
| Q43218675 | First-line chemotherapy for ovarian cancer - the controversy continues |
| Q34462139 | Future directions for the management of ovarian cancer |
| Q39788259 | Garlic constituent diallyl trisulfide induced apoptosis in MCF7 human breast cancer cells |
| Q28542669 | Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells |
| Q34813092 | Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients. |
| Q73540284 | Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors |
| Q58766772 | Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance |
| Q35726998 | Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes |
| Q48116981 | High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy. |
| Q34162123 | Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors |
| Q73574759 | Hyperproliferation and p53 status of lens epithelial cells derived from alphaB-crystallin knockout mice |
| Q73263605 | IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects |
| Q47772595 | Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas |
| Q34727266 | Importance of detecting numerical versus structural chromosome aberrations |
| Q47157561 | In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell |
| Q28352698 | Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity |
| Q28539684 | Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade |
| Q36292481 | Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells |
| Q35797390 | Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein |
| Q31137239 | Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis |
| Q36114881 | Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors |
| Q30783266 | Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines |
| Q74288176 | Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? |
| Q43901360 | Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer |
| Q40794489 | Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity |
| Q38882347 | Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor |
| Q73093705 | MEK inhibition enhances paclitaxel-induced tumor apoptosis |
| Q36201008 | Mammary Stem Cells and Tumor-Initiating Cells Are More Resistant to Apoptosis and Exhibit Increased DNA Repair Activity in Response to DNA Damage |
| Q77994535 | Methyl methanesulfonate and hydrogen peroxide differentially regulate p53 accumulation in hepatoblastoma cells |
| Q27690249 | Microtubule-binding agents: a dynamic field of cancer therapeutics |
| Q34285363 | Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. |
| Q35645461 | Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult |
| Q35633680 | Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 |
| Q33186850 | Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy |
| Q41931874 | Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents |
| Q33618285 | Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients |
| Q40711094 | Mutations of TP53 do not correlate with the sensitivity to paclitaxel--a study using 27 gynaecological cancer cell lines. |
| Q64083387 | NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer |
| Q42804466 | Nicotinamide- and caspase-mediated inhibition of poly(ADP-ribose) polymerase are associated with p53-independent cell cycle (G2) arrest and apoptosis |
| Q40343222 | Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. |
| Q38407182 | Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients |
| Q36254803 | Nucleotide excision repair and anti-cancer chemotherapy |
| Q42818247 | Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. |
| Q35166813 | Ovarian cancer: strategies for overcoming resistance to chemotherapy |
| Q28613291 | Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase |
| Q39604427 | Overexpression of simian virus 40 small-T antigen blocks centrosome function and mitotic progression in human fibroblasts |
| Q55111247 | P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. |
| Q33913135 | P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation |
| Q41129549 | P53 protein expression in human multidrug-resistant CEM lymphoblasts |
| Q34539978 | P53: an ubiquitous target of anticancer drugs |
| Q40775266 | Paclitaxel and concurrent radiation for gastric cancer |
| Q35634812 | Paclitaxel and concurrent radiation in upper gastrointestinal cancers |
| Q40749281 | Paclitaxel combined with fractionated radiation in vitro: a study with vulvar squamous cell carcinoma cell lines |
| Q52826331 | Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. |
| Q40939584 | Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation |
| Q35852309 | Pathways of apoptotic and non-apoptotic death in tumour cells |
| Q35121876 | Persistent mitochondrial hyperfusion promotes G2/M accumulation and caspase-dependent cell death |
| Q73934711 | Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cance |
| Q41726923 | Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation |
| Q54111946 | Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. |
| Q40920736 | Poor prognosis Ewing's sarcoma and peripheral primitive neuroectodermal tumours (PNET). |
| Q36673922 | Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints |
| Q33893910 | Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel |
| Q24801874 | Predictive factor for the response to adjuvant therapy with emphasis in breast cancer |
| Q40765650 | Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors |
| Q36245341 | Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial |
| Q36421995 | Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro |
| Q35889568 | Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial |
| Q34001266 | Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer |
| Q57011065 | Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma |
| Q37208757 | Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. |
| Q34605615 | Regulation of apoptosis by the papillomavirus E6 oncogene |
| Q39583941 | Regulation of proliferation-survival decisions during tumor cell hypoxia |
| Q31655353 | Repression of human reduced folate carrier gene expression by wild type p53. |
| Q41735655 | Role of apoptotic response in cellular resistance to cytotoxic agents |
| Q73164603 | Role of p53 in drug resistance in ovarian cancer |
| Q37630572 | Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer |
| Q36613525 | SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer |
| Q38262971 | SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways. |
| Q40956127 | SV40 virus transformation down-regulates endothelin receptor |
| Q39562856 | Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells. |
| Q43690855 | Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin |
| Q74273660 | Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells |
| Q44098571 | Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel |
| Q33369125 | Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study |
| Q24679386 | Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells |
| Q101133368 | Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer |
| Q33898768 | Soft tissue sarcomas and p53 mutations |
| Q35080295 | Study of suboptimum treatment response: lessons from breast cancer |
| Q44943097 | Subadditive interaction of radiation and Taxol in vitro |
| Q38402017 | Sulforaphane sensitizes human breast cancer cells to paclitaxel-induced apoptosis by downregulating the NF-κB signaling pathway |
| Q36294095 | Suppression of p53 function in normal human mammary epithelial cells increases sensitivity to extracellular matrix-induced apoptosis |
| Q31384854 | Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels |
| Q53588202 | Swearing off the oath? |
| Q36565011 | Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability |
| Q36108564 | Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts |
| Q33317044 | TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. |
| Q34234217 | TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial |
| Q22009104 | TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line |
| Q34348279 | Targeting apoptosis in prostate cancer |
| Q94461581 | Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation |
| Q36012041 | Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis |
| Q34180782 | Taxanes in combined modality therapy for solid tumors |
| Q33800977 | Taxanes: an overview of the pharmacokinetics and pharmacodynamics |
| Q40811036 | Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. |
| Q43557531 | Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition |
| Q41064243 | Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest |
| Q77753611 | The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin |
| Q21129297 | The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis |
| Q51497796 | The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. |
| Q40973393 | The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis |
| Q73062597 | The ins and outs of p53 |
| Q41100367 | The mammalian metabolite, 2-methoxyestradiol, affects P53 levels and apoptosis induction in transformed cells but not in normal cells |
| Q73557025 | The mitotic spindle and DNA damage-induced apoptosis |
| Q28545041 | The novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivo |
| Q37356294 | The p53 breast cancer tissue biomarker in Indian women |
| Q28282671 | The papillomavirus E6 proteins |
| Q43854589 | The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q36614217 | The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line. |
| Q37895519 | The role of Tau protein in resistance to paclitaxel |
| Q41558368 | The transport and binding of taxol |
| Q38337659 | The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. |
| Q36115202 | Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status |
| Q40892936 | Transcriptional activation of p21WAF1 by PTEN/MMAC1 tumor suppressor |
| Q37180861 | Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe |
| Q43190925 | Treating breast cancer before surgery |
| Q37602289 | Triple negative breast cancers: clinical and prognostic implications. |
| Q57140329 | Triple-negative breast cancer |
| Q34958852 | Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes |
| Q28652788 | Use of a small molecule cell cycle inhibitor to control cell growth and improve specific productivity and product quality of recombinant proteins in CHO cell cultures |
| Q43981311 | Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel |
| Q77495165 | Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial |
| Q37225088 | Ziyuglycoside II inhibits the growth of human breast carcinoma MDA-MB-435 cells via cell cycle arrest and induction of apoptosis through the mitochondria dependent pathway |
| Q36617940 | c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. |
| Q34192806 | cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity |
| Q34489153 | miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1. |
| Q34722558 | miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma |
| Q41073992 | p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors |
| Q36946749 | p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells |
| Q58813489 | p53 activity and chemotherapy |
| Q71031884 | p53 and chemosensitivity |
| Q36644176 | p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients |
| Q44417787 | p53 expression and resistance against paclitaxel in patients with metastatic breast cancer |
| Q74013106 | p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer |
| Q73375715 | p53 in drug resistance in ovarian cancer |
| Q40926531 | p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma |
| Q74650373 | p53 mutations predict non-small cell lung carcinoma response to radiotherapy |
| Q33766312 | p53 suppresses structural chromosome instability after mitotic arrest in human cells |
| Q37385633 | p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells |
| Q28292014 | p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma |
| Q36605767 | p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents |
| Q36573439 | p53-independent apoptosis induced by paclitaxel through an indirect mechanism |
| Q33545318 | p53-oriented cancer therapies: current progress |
| Q73549433 | p53-regulated GML gene expression in non-small cell lung cancer. a promising relationship to cisplatin chemosensitivity |
| Q36058740 | pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy |
Search more.